Lucid Diagnostics to Participate in Fireside Chat at Healthcare Conference

The cancer prevention company will discuss its esophageal cancer screening technology at the 25th Annual Needham Virtual Healthcare Conference.

Apr. 9, 2026 at 12:21pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image of a human esophagus, its internal structures illuminated as glowing lines against a dark background, conceptually representing the company's innovative approach to early cancer detection.Lucid Diagnostics' esophageal cancer screening technology aims to detect precancerous changes early, before they progress to deadly disease.NYC Today

Lucid Diagnostics Inc., a commercial-stage cancer prevention medical diagnostics company, announced that its Chairman and CEO Lishan Aklog, M.D. will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026. The live webcast will be available on the company's Investor Relations website.

Why it matters

Lucid Diagnostics is focused on developing early detection tools for esophageal precancer and cancer, which affects millions of people with chronic heartburn. The company's EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device represent the first commercially available technologies aimed at preventing cancer deaths through widespread screening.

The details

The fireside chat will take place at 10:15 AM EDT on April 16, 2026 and will be webcast live. A replay of the webcast will be available on Lucid's website for 30 days following the event.

  • The fireside chat will take place on April 16, 2026 at 10:15 AM EDT.

The players

Lucid Diagnostics Inc.

A commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM).

Lishan Aklog, M.D.

The Chairman and Chief Executive Officer of Lucid Diagnostics Inc.

Got photos? Submit your photos here. ›

The takeaway

Lucid Diagnostics' participation in this high-profile healthcare conference demonstrates the company's commitment to advancing its innovative esophageal cancer screening technologies and raising awareness of its mission to prevent cancer deaths through early detection.